My Dear Friends, Welcome!
I’m truly excited to see that we are convening
the second Biotech & Life Sciences Global Venture Congress.
We will be doing what we have done before: take pleasure in the
company of a limited but exciting group of extraordinarily accomplished
individuals from around the globe.
The Global Venture Congress conference is an event
we would like to define and call "the world’s platform
for exploring the frontiers” in which we express our optimism
for the future and extend our support to usher in the future of
innovation faster. Our dedication and commitment is well known
to more than 15,000 participants who have attended our events,
starting from our humble beginning in a small bar in NYC in 1999.
This includes all the delegates who participated
in our first Biotech Congress held last year -- biotech and life
science executives, investors, professors, entrepreneurs, Nobel
laureates -- the very people who helped make the biotech industry
the key sector it is today. One delegate from the 2004 conference
said, "just being in the room with so many smart people and
interesting ideas gives a sense of exhilaration."
This year we have another great global audience
for which I am excited. Delegates include representatives from
South Korea, Russia, Switzerland, China, and the UK.
It’s hard to miss the recent investment activity
in the Biotech & Life Sciences space. Also it’s noteworthy
to point out that the VC industry is just starting in India and
is expected to grow quickly. All indicators suggest that more
and more investments are expected to happen all over the world.
This is great news for entrepreneurs who have started or are planning
to start a Biotech/Life Science venture.
There is a stream of exciting discoveries and development
news coming from all sectors. It’s note worthy here to mention
a few such examples. 1) There has been development of rapid DNA
sequencing technology through the use of nanotechnology. 2) In
November 2004, scientists in Cambridge, MA had a breakthrough.
They found a way to slip a biotech drug intravenously past the
body's defenses. Now nearing clinical trials, intravenous RNAi
could be the key to defeating cancer. 3) There have been telerobotic
surgeries performed in patients' homes by world-class doctors
at a fraction of the cost of a hospital visit. 4) The news of
stem cell research development from South Korea is the most important
of all in my view. The sooner we resolve the ethical issue of
stem cell research, the sooner we can find various treatments
to life threatening diseases through the use of stem cells.
The best is yet to come - a lot of exciting development
can be expected in the fields of Medical Device, Specialty Pharma,
Drug Design, Genomics, Stem Cells, Proteomics, Biomedicine and
Nanotech-Biotech.
As always, those who join us in New York will rub
elbows with people they regard as peers. Conference delegates
are going to be learning from one another and perhaps making plans
for new business and research ventures.
I would like to thank you all for participating
in this great endeavor.
Best regards,
Gyan
Parida, Ph.D., MBA
Chairman, Global Venture Congress
President/CEO, Silicon Alley Entrepreneurs Club (SAEC)